IL293477B2 - New frameworks for antibodies - Google Patents

New frameworks for antibodies

Info

Publication number
IL293477B2
IL293477B2 IL293477A IL29347722A IL293477B2 IL 293477 B2 IL293477 B2 IL 293477B2 IL 293477 A IL293477 A IL 293477A IL 29347722 A IL29347722 A IL 29347722A IL 293477 B2 IL293477 B2 IL 293477B2
Authority
IL
Israel
Prior art keywords
antibody
sequence
seq
nucleic acid
framework region
Prior art date
Application number
IL293477A
Other languages
English (en)
Hebrew (he)
Other versions
IL293477A (en
IL293477B1 (en
Inventor
Urech David
Meyer Sebastian
Original Assignee
Numab Therapeutics AG
Urech David
Meyer Sebastian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG, Urech David, Meyer Sebastian filed Critical Numab Therapeutics AG
Publication of IL293477A publication Critical patent/IL293477A/en
Publication of IL293477B1 publication Critical patent/IL293477B1/en
Publication of IL293477B2 publication Critical patent/IL293477B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL293477A 2013-06-26 2014-06-26 New frameworks for antibodies IL293477B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13003264 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks

Publications (3)

Publication Number Publication Date
IL293477A IL293477A (en) 2022-08-01
IL293477B1 IL293477B1 (en) 2024-07-01
IL293477B2 true IL293477B2 (en) 2024-11-01

Family

ID=48699516

Family Applications (3)

Application Number Title Priority Date Filing Date
IL293477A IL293477B2 (en) 2013-06-26 2014-06-26 New frameworks for antibodies
IL243311A IL243311B (en) 2013-06-26 2014-06-26 Novel antibody frameworks
IL313351A IL313351A (en) 2013-06-26 2014-06-26 New frameworks for antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL243311A IL243311B (en) 2013-06-26 2014-06-26 Novel antibody frameworks
IL313351A IL313351A (en) 2013-06-26 2014-06-26 New frameworks for antibodies

Country Status (12)

Country Link
US (3) US10174102B2 (enExample)
EP (1) EP3013864A1 (enExample)
JP (4) JP6708544B2 (enExample)
KR (4) KR102286053B1 (enExample)
CN (2) CN105579472B (enExample)
AU (2) AU2014301629B2 (enExample)
CA (1) CA2914829A1 (enExample)
HK (1) HK1218549A1 (enExample)
IL (3) IL293477B2 (enExample)
NZ (1) NZ714320A (enExample)
SG (2) SG11201509899PA (enExample)
WO (1) WO2014206561A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102286053B1 (ko) 2013-06-26 2021-08-04 누맙 세러퓨틱스 아게 신규한 항체 기본구조
EA201890041A1 (ru) 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
KR20180111870A (ko) 2016-02-25 2018-10-11 셀 메디카 스위처란트 아게 Pd-l1에 대한 결합 성분
CN109153718B (zh) 2016-03-17 2022-02-08 努玛治疗有限公司 抗TNFα抗体及其功能片段
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
ES2836349T3 (es) 2016-03-17 2021-06-24 Tillotts Pharma Ag Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos
HUE052869T2 (hu) 2016-03-17 2021-05-28 Tillotts Pharma Ag TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei
KR102392746B1 (ko) 2016-03-17 2022-04-29 누맙 이노베이션 아게 항-TNFα-항체 및 이의 기능성 단편
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
ES3015094T3 (en) 2017-06-05 2025-04-29 Numab Therapeutics AG Anti-hsa antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
US11319371B2 (en) 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US12098203B2 (en) 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
KR102763369B1 (ko) 2017-06-25 2025-02-05 시스트이뮨, 인코포레이티드 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
CN110799540B (zh) * 2017-06-25 2024-02-13 西雅图免疫公司 多特异性抗体及其制备和使用方法
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN120025437A (zh) 2019-01-31 2025-05-23 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
AU2021413899A1 (en) * 2020-12-30 2023-08-03 Ascendo Biotechnology, Inc. Monoclonal antibody against human mac-1 and uses thereof
CA3208905A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
JP2024509971A (ja) 2021-03-11 2024-03-05 アイジェニックス， インコーポレイテッド アレルギー応答を予測するための方法およびシステム
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
WO2024098026A2 (en) * 2022-11-04 2024-05-10 Mink Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CA2533830A1 (en) 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
MX343879B (es) 2007-05-21 2016-11-25 Alderbio Holdings Llc Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
PT2307454T (pt) 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o vegf
KR101834797B1 (ko) * 2008-06-25 2018-03-07 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
CA2798120A1 (en) * 2010-04-30 2011-11-03 Paul P. Tamburini Antibodies having reduced immunogenicity in a human
EP2726504A1 (en) * 2011-05-27 2014-05-07 Dutalys Antibodies with improved folding stability
KR102286053B1 (ko) 2013-06-26 2021-08-04 누맙 세러퓨틱스 아게 신규한 항체 기본구조
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORRAS, LEO, ET AL., GENERIC APPROACH FOR THE GENERATION OF STABLE HUMANIZED SINGLE-CHAIN FV FRAGMENTS FROM RABBIT MONOCLONAL ANTIBODIES., 7 January 2010 (2010-01-07) *

Also Published As

Publication number Publication date
KR20210097829A (ko) 2021-08-09
US20190119359A1 (en) 2019-04-25
CN113943366A (zh) 2022-01-18
US10174102B2 (en) 2019-01-08
WO2014206561A8 (en) 2016-02-18
AU2020202770A1 (en) 2020-05-14
IL243311A0 (en) 2016-03-31
US20160130326A1 (en) 2016-05-12
KR20220029763A (ko) 2022-03-08
CA2914829A1 (en) 2014-12-31
KR102286053B1 (ko) 2021-08-04
IL243311B (en) 2022-07-01
CN105579472A (zh) 2016-05-11
NZ714320A (en) 2022-02-25
IL313351A (en) 2024-08-01
CN105579472B (zh) 2021-10-22
AU2014301629A1 (en) 2015-12-10
IL293477A (en) 2022-08-01
EP3013864A1 (en) 2016-05-04
AU2014301629B2 (en) 2020-02-06
SG11201509899PA (en) 2016-01-28
JP2016523537A (ja) 2016-08-12
AU2020202770B2 (en) 2023-01-05
JP6708544B2 (ja) 2020-06-10
KR20240000622A (ko) 2024-01-02
IL293477B1 (en) 2024-07-01
JP2024026176A (ja) 2024-02-28
KR20160024923A (ko) 2016-03-07
WO2014206561A1 (en) 2014-12-31
HK1218549A1 (zh) 2017-02-24
CN113943366B (zh) 2024-12-13
JP2022028659A (ja) 2022-02-16
US11427628B2 (en) 2022-08-30
SG10201811017QA (en) 2019-01-30
JP2019201643A (ja) 2019-11-28
US20230212265A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
US20230212265A1 (en) Novel antibody frameworks
JP2016523537A5 (enExample)
CA3073882A1 (en) Novel stable antibody variable domain framework combinations
CA2853383A1 (en) Bispecific antibodies comprising two paratopes in one complementary vh-vl pair
IL271127B1 (en) New anti-HSA antibodies
IL271128B1 (en) New anti-3CD antibodies
IL270308B1 (en) Anti-interferon gamma antibodies and uses thereof
WO2018224439A1 (en) Novel anti-hsa antibodies
IL256263A (en) Cys80-linked immunoglobulins
IL298076A (en) Multispecific antibodies
HK40023336A (en) Anti-hsa antibodies
HK40023336B (en) Anti-hsa antibodies